Track Immunovant, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Immunovant, Inc. IMVT · Stock Open Immunovant, Inc. in new tab

41.82 USD
Add to portfolio
EPS
-2.81
P/B
10.00
ROE
-80.10
Beta
0.81
Target Price
47.88 USD
Immunovant, Inc. logo

Immunovant, Inc.

🧾 Earnings Recap – Q1 2027

Roivant's stock edged up modestly by 1.7% following a quiet quarter that met expectations without delivering clear catalysts to drive a stronger move. Investors appear to be in a wait-and-see mode ahead of several key data readouts and potential product launches slated for the second half of 2026.

  • The quarter was described as “quiet,” with no new significant commercial or clinical breakthroughs reported.
  • Brexpiprazole is on track for an imminent launch in dermatomyositis, pending FDA approval, with additional Phase III enrollment advancing in cutaneous sarcoidosis.
  • Several important Phase III data milestones are expected in the second half of 2026 for brexpiprazole in indications including NIU, PH-ILD, and CLE.
  • Progress continues on the Moderna settlement and ongoing litigation against Pfizer and BioNTech.
  • Investors are likely awaiting the upcoming “busier” period in 2H26 and beyond, given the pipeline’s heavy event schedule.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 9, 2026
EPS-2.81
Book Value4.18
Price to Book10.00
Debt/Equity0.01
% Insiders56.020%
Estimates
Forward P/E-16.73
Forward EPS-2.50
Target Mean Price47.88

DCF Valuation

Tweak assumptions to recompute fair value for Immunovant, Inc. (IMVT)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Immunovant, Inc. Logo Immunovant, Inc. Analysis (IMVT)

United States Health Care Official Website Stock

Is Immunovant, Inc. a good investment? Immunovant, Inc. (IMVT) is currently trading at 41.82 USD. Market analysts have a consensus price target of 47.88 USD. This suggests a potential upside from current levels.

Earnings Schedule: Immunovant, Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -2.50.

Investor FAQ

Does Immunovant, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Immunovant, Inc.?

Immunovant, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -2.81.

Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Exchange Ticker
NMS (United States) IMVT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion